36X 주식 개요 임상 단계의 생명공학 회사인 어센티지 파마 그룹 인터내셔널은 중국 본토에서 암, 만성 B형 간염 바이러스(HBV), 노화 관련 질환에 대한 치료법을 개발하는 회사입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Ascentage Pharma Group International 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Ascentage Pharma Group International 과거 주가 현재 주가 HK$5.20 52주 최고치 HK$5.75 52주 최저치 HK$1.86 베타 1.12 1개월 변경 10.64% 3개월 변경 사항 6.56% 1년 변경 사항 n/a 3년 변화 88.41% 5년 변화 75.68% IPO 이후 변화 51.12%
최근 뉴스 및 업데이트
Ascentage Pharma Group International Announces Board and Committee Changes, Effective January 2, 2025 Jan 02 Ascentage Pharma Group International has filed a Follow-on Equity Offering in the amount of $100 million. Dec 28
Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax Dec 10
Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List Nov 28
Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors Nov 27
Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC Oct 08 더 많은 업데이트 보기
Ascentage Pharma Group International Announces Board and Committee Changes, Effective January 2, 2025 Jan 02 Ascentage Pharma Group International has filed a Follow-on Equity Offering in the amount of $100 million. Dec 28
Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax Dec 10
Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List Nov 28
Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors Nov 27
Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC Oct 08
First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023) Oct 03
Forecast to breakeven in 2026 Aug 28
First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023) Aug 26
New major risk - Revenue and earnings growth Aug 23
Ascentage Pharma Clears to Initiate A Registrational Phase III Study of Lisaftoclax, by the Center for Drug Evaluation of China National Medical Products Administration Aug 13
Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024 Aug 09
New minor risk - Shareholder dilution Jun 24
Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351) Jun 18
Ascentage Pharma Group International Announces Board and Committee Changes Jun 13
New major risk - Share price stability Jun 09 Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%
Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting May 25
Ascentage Pharma Group International, Annual General Meeting, May 10, 2024 Mar 28
Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022) Mar 28
Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting Mar 06
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia Feb 14
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN) Jan 17
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib Dec 15
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR Dec 11
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication Nov 25
China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients Nov 18 Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports
Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc Oct 24
Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia Oct 18
Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE Oct 13
First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022) Sep 24
Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial Aug 22 Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023 Aug 10
Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax Aug 08
New minor risk - Share price stability Jul 26
Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All) Jul 06
Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC Jun 06
Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST Jun 01
Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting May 29
Full year 2022 earnings released: CN¥3.35 loss per share (vs CN¥3.07 loss in FY 2021) Mar 23 Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million. Feb 02
Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List Jan 19
Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax Dec 14 Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib
Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License Nov 28
Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies Nov 10
Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B Nov 08
Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb Nov 07 Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting Nov 04
Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting Oct 20 Ascentage Pharma Announces Phase I/Ii Data of Olverembatinib (Hqp1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-In-Class Potential
First half 2022 earnings released: CN¥1.54 loss per share (vs CN¥1.53 loss in 1H 2021) Aug 28
Ascentage Pharma Group International to Report Q2, 2022 Results on Aug 26, 2022 Aug 17
High number of new directors Jul 31
Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada Jul 22
Ascentage Pharma Announces China National Medical Products Administration Accepts and Grants Priority Review Designation to Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML Jul 20 Ascentage Pharma Group International Announces Ind Clearance by the Us Fda for First-In-Human Study of Novel Eed Inhibitor Apg-5918
Ascentage Pharma Group International Releases Results from A Phase I Study of the Company's Novel Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R Nhl) at the 2022 European Hematology Association Hybrid Congress Jun 13
Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL Jun 09
Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC Jun 08 Ascentage Pharma Group International Releases the Updated Results from A Phase II Study of the Mdm2-P53 Inhibitor Alrizomadlin (APG-115) Plus Pembrolizumab in Adults and Children with Various Solid Tumors in A Poster Discussion Session At the ASCO Annual Meeting
Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development May 27
High number of new directors May 26
Ascentage Pharma Group to Present Latest Clinical Data of Bcl-2 Inhibitorlisaftoclax (Apg-2575) in Patients with Relapsed/Refractory Non-Hodgkinlymphomas At 2022 European Hematology Association Hybrid Congress May 24
Ascentage Pharma Group International Announces Management Changes, Effective May 20, 2022 May 20
Ascentage Pharma Group International Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in Embo Molecular Medicine May 19
Less than half of directors are independent May 02
Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 Apr 14
Ascentage Pharma Group International, Annual General Meeting, May 19, 2022 Mar 23
Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including A China Study Demonstrating Complete Responses Dec 15
Ascentage Pharma Announces CDE's Approval for the Phase II Pivotal Study in China of the Bcl-2 Inhibitor Lisaftoclax (APG-2575) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Dec 13
Clover Biopharmaceuticals, Ltd. and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human Trail-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis Dec 10
Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib Dec 01
Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Grants Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma Sep 24
Ascentage Pharma Reports the Phase Ib Results of the Dual Bcl-2/Bcl-Xl Inhibitor, Apg-1252 Sep 10
First half 2021 earnings released: CN¥1.53 loss per share (vs CN¥1.53 loss in 1H 2020) Aug 28
Ascentage Pharma Group International Receives Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma Jul 23
Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors Jun 15 Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs
Non-Executive Director recently sold €2.0m worth of stock Jun 01
Forecast to breakeven in 2023 May 26
Ascentage Pharma to Announce Updated Results Demonstrating Clinical Potential of Alrizomadlin (APG-115) Plus Pembrolizumab in Patients with Advanced Solid Tumors that Had Failed Immunotherapies in Oral Presentation May 21
Non-Executive Director has left the company Apr 07
Full year 2020 earnings released: CN¥3.14 loss per share (vs CN¥12.69 loss in FY 2019) Apr 03
Ascentage Pharma Group International to Report Fiscal Year 2020 Results on Mar 31, 2021 Mar 20 주주 수익률 36X DE Biotechs DE 마켓 7D -1.0% 2.5% -0.4% 1Y n/a -10.2% 7.9%
전체 주주 수익률 보기
수익률 대 산업: German Biotechs 산업에 대해 36X 의 성과를 판단하기에는 데이터가 부족합니다.
수익률 대 시장: German 시장에 대해 36X 의 성과를 판단하기에는 데이터가 부족합니다.
가격 변동성 Is 36X's price volatile compared to industry and market? 36X volatility 36X Average Weekly Movement 9.5% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: 36X 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: 36X 의 주간 변동성 ( 9% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 임상 단계의 생명공학 회사인 어센티지 파마 그룹 인터내셔널은 중국 본토에서 암, 만성 B형 간염 바이러스(HBV), 노화 관련 질환 치료제를 개발하는 회사입니다. 이 회사의 주요 제품 후보로는 T315I 돌연변이를 포함한 BCR-ABL1 돌연변이를 표적으로 하는 BCR-ABL 억제제인 HQP1351이 있습니다. 또한 혈액암 및 고형 종양에 대한 경구용 Bcl-2 선택적 억제제인 APG-2575, 고형 종양 및 혈액암 치료를 위한 MDM2-p53 단백질 단백질 상호작용 저해제인 APG-115를 개발하고 있으며, 혈액암 및 혈액학 악성 종양에 대한 경구용 저분자 억제제인 APG-1252도 개발 중입니다; 소세포폐암, 비소세포폐암, 신경내분비종양, 비호지킨 림프종 치료를 위한 Bcl-2 및 Bcl-xL 단백질의 이중 억제를 통한 세포사멸 회복 저분자 약물인 APG-1252를 개발하고 있습니다.
자세히 보기 Ascentage Pharma Group International 기본 사항 요약 Ascentage Pharma Group International 의 수익과 매출은 시가총액과 어떻게 비교하나요? 36X 기본 통계 시가총액 €1.69b 수익(TTM ) -€47.76m 수익(TTM ) €119.72m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 36X 손익 계산서(TTM ) 수익 CN¥903.03m 수익 비용 CN¥27.45m 총 이익 CN¥875.58m 기타 비용 CN¥1.24b 수익 -CN¥360.28m
주당 순이익(EPS) -1.16 총 마진 96.96% 순이익 마진 -39.90% 부채/자본 비율 216.3%
36X 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/05 08:52 장 마감 주가 2025/01/03 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Ascentage Pharma Group International 13 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Yang Huang BofA Global Research Jin Zhang China International Capital Corporation Limited Wangbin Zhou China International Capital Corporation Limited
10 더 많은 분석가 보기 
